Brukinsa 80 mg – DIN 02512963
Brukinsa is Zanubrutinib 80 mg (capsule), sold in Canada. It is used for mantle-cell lymphoma. It is supplied by Beone Medicines I GmbH. We don't have a photo or description of what this pill looks like yet, so check the name and code on the box or bottle, and ask a pharmacist before taking it. Its official Health Canada listing links to the product monograph, which describes the tablets.
Sold in Canada
Zanubrutinib 80 mg
- Brand
- Brukinsa
- Strength
- 80 mg
- Used for
- Mantle-cell lymphoma
- Form
- Capsule
- Manufacturer
- Beone Medicines I GmbH
- Drug class
- Cancer medicine (kinase inhibitor)
- Sold in
- Canada
- DIN
- 02512963
Source: Health Canada's Drug Product Database. Last checked .
Report a mistake
What is Zanubrutinib used for?
Zanubrutinib is used for mantle-cell lymphoma.
- Medicine type
- Cancer medicine (kinase inhibitor)
Official uses from the US prescribing label
Mantle Cell Lymphoma
BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Waldenström's Macroglobulinemia
BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM).
Marginal Zone Lymphoma
BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen.
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BRUKINSA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Follicular Lymphoma
BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy.
This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
From the FDA-approved label on DailyMed (published Sep 14, 2026).
Doctors sometimes prescribe a medicine for other reasons too. If you are not sure what yours is for, ask your pharmacist.
Is this your medicine? Check the box
- The box or bottle shows DIN 02512963.
- It names Brukinsa, Zanubrutinib 80 mg.
- A loose pill is a different matter: without a description of its markings, a pharmacist has to confirm what it is.
Sold in Canada as Brukinsa by Beone Medicines I GmbH.
In Canada: prescription only.
Ingredients
Active: Zanubrutinib